Method to reduce myocardial injury during acute myocardial infarction

• US 6,090,777 A
• Filed: 04/02/1996
• Issued: 07/18/2000
• Est. Priority Date: 09/01/1993
• Status: Expired due to Term

• Current Assignee: Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis
• Original Assignee: Stiching Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis
• Inventors: Hermens, Willem Theodoor, Hack, Cornelis Erik
• Primary Examiner(s): Witz, Jean C.
• Application Number:
  US08/604,933
• Time in Patent Office: 1,568 Days
• Field of Search: 514/2, 514/8, 530/380, 530/417
• US Class Current: 514/13.5
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A therapeutic or prophylactic treatment method of acute myocardial infarction, comprising administering exogenous C1-esterase inhibitor, alone or in combination with other drugs, to a patient with acute myocardial infarction or to a patient at risk for acute myocardial infarction. The treatment inhibits the inflammatory reaction, more specifically the activation of the complement system, which occurs in the course of acute myocardial infarction. The C1-esterase inhibitor may include C1-esterase inhibitor purified from plasma or other biological materials, or recombinant C1-esterase inhibitor, or recombinant variants derived therefrom, or recombinant constructs of other inhibitors having a specificity similar to C1-esterase inhibitor.

Claims

1. A therapeutic or prophylactic treatment method of acute myocardial infarction, which method comprises administering exogenous C1-esterase inhibitor, alone or in combination with other drugs, to a patient with acute myocardial infarction or to a patient at risk for acute myocardial infarction.

2. The method of claim 1 where said C1-esterase inhibitor is administered in an amount sufficient to reduce myocardial cell injury.

3. The method of claim 1 where said C1-esterase inhibitor is administered by intravenous injection, usually in an amount in the range of 30 to 40 U per kg of body weight.

4. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human plasma.

5. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

6. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal plasma.

7. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

8. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human biological material other than plasma.

9. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from human biological material other than plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

10. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal biological material other than plasma.

11. The method of claim 1 where said C1-esterase inhibitor is C1-esterase inhibitor purified from animal biological material other than plasma, and thereafter modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

12. The method of claim 1 where said C1-esterase inhibitor is recombinant C1-esterase inhibitor.

13. The method of claim 1 where said C1-esterase inhibitor is recombinant C1-esterase inhibitor modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

14. The method of claim 1 where said C1-esterase inhibitor is a variant of recombinant C1-esterase inhibitor in which C1-esterase inhibitor activity has been maintained.

15. The method of claim 1 where said C1-esterase inhibitor is a variant of recombinant C1-esterase inhibitor modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

16. The method of claim 1 where said C1-esterase inhibitor is recombinant proteinase inhibitor other than C1-esterase inhibitor, mutated to yield C1-esterase inhibitor activity.

17. The method of claim 1 where said C1-esterase inhibitor is recombinant proteinase inhibitor other than C1-esterase inhibitor, mutated to yield C1-esterase inhibitor activity and modified by chemical or other manipulations with maintenance of C1-esterase inhibitor activity.

18. The method of claim 1 where said C1-esterase inhibitor is administered in combination with a substance which improves the blood flow to the myocardium, such as tissue plasminogen activator, urokinase or streptokinase.

19. The method of claim 1 where said C1-esterase inhibitor is administered in combination with a substance having anti-inflammatory properties, such as an oxygen radical scavenger or a cytokine antagonist.

20. A pharmaceutical composition comprising exogenous C1-esterase inhibitor, a carrier and a substance capable of improving blood flow to the myocardium.

21. A pharmaceutical composition comprising exogenous C1-esterase inhibitor, a carrier and a substance having anti-inflammatory properties.